Venous thromboembolism as a trigger for acute cardiac decompensation during cancer hospitalizations: A National Inpatient Sample analysis, 2018–2022.

C Christopher Aboujaoude (HCA Sunrise Health GME Consortium - MountainView Hospital, Las Vegas, NV) S Sharnvir Chattha (HCA Sunrise Health GME Consortium - MountainView Hospital, Las Vegas, NV) B Boone Singtong (HCA Sunrise Health GME Consortium - MountainView Hospital, Las Vegas, NV) D Daniel Thomas Jones (HCA Sunrise Health GME Consortium - MountainView Hospital, Las Vegas, NV) P Pinak Shah (From Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, NJ (P.G.); Columbia University Medical Center/New York Presbyterian Hospital (A.S., R.T.H., M.B.L.), the Cardiovascular Research Foundation (D.J.C., R.T.H., B.R., M.B.L.), and Weill Cornell Medicine (B.R.), New York, and St. Francis Hospital and Heart Center, Roslyn (D.J.C.) — all in New York; University of Colorado Health, Medical Center of the Rockies, Loveland (J.B.O.); Laval University, Quebec, QC (P.P.), St. Paul’s Hospital, University of British Columbia, Vancouver (P.B., J.L.), and McMaster University, Hamilton, ON (T.S.) — all in Canada; Vanderbilt University Medical Center, Nashville (B.R.L., K.G.); Emory University, Atlanta (V.B.); the Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, Stanford (W.F.F.), VA Palo Alto Health Care System, Palo Alto (W.F.F.), California Pacific Medical Center, San Francisco (D.V.D.), Cedars–Sinai Medical Center, Los Angeles (R.R.M.), and Edwards ...) K Kyaw Zin Thein (3Comprehensive Cancer Centers of Nevada, Division of Hematology and Medical Oncology, Las Vegas, United States)

Abstract

e23099 Background: Venous thromboembolism (VTE) is a common complication of malignancy, but its role as a trigger for acute cardiac and hemodynamic decompensation during hospitalization is poorly defined. Most studies emphasize VTE incidence rather than downstream inpatient severity. This study evaluated whether pulmonary embolism (PE) and deep vein thrombosis (DVT) are associated with disproportionate inpatient deterioration in hospitalized patients with cancer. Methods: We conducted a serial cross-sectional analysis of adult hospitalizations with a principal diagnosis of malignancy in the 2018–2022 Healthcare Cost and Utilization Project National Inpatient Sample. VTE was identified using any-diagnosis ICD-10-CM codes for PE (I26*) and DVT (I82*) and categorized as no VTE, DVT only, PE only, or PE with concurrent DVT. Outcomes included All Patient Refined Diagnosis Related Group (APR-DRG) severity, extreme severity (APR-DRG level 4), in-hospital mortality, shock, mechanical ventilation, length of stay (LOS), and hospitalization cost. Survey-weighted multivariable regression adjusted for demographics, payer, income quartile, admission type, cancer subtype, hospital characteristics, and year. Results: Among 961,848 unweighted cancer hospitalizations representing 4,809,239 admissions nationally, VTE occurred in 5.51 percent, including PE only in 2.00 percent, DVT only in 3.85 percent, and PE with DVT in 0.52 percent. Inpatient severity increased stepwise across VTE phenotypes. Mean APR-DRG severity increased from 2.51 with no VTE to 3.35 with DVT only, 3.63 with PE only, and 3.80 with PE plus DVT. Extreme severity occurred in 3.09 percent without VTE versus 8.49 percent, 11.68 percent, and 15.20 percent, respectively. Mortality increased from 4.01 percent to 9.67 percent, 13.76 percent, and 12.69 percent, with higher rates of shock and mechanical ventilation. LOS and costs were highest among PE plus DVT admissions. After adjustment, PE only was independently associated with extreme severity (OR 8.39, 95% CI 7.64 to 9.22), shock (OR 2.81, 95% CI 2.55 to 3.09), mechanical ventilation (OR 2.98, 95% CI 2.77 to 3.21), and mortality (OR 2.95, 95% CI 2.80 to 3.12). PE plus DVT conferred the highest risk of shock (OR 4.14, 95% CI 3.69 to 4.64) and extreme severity (OR 18.85, 95% CI 16.07 to 22.10). Conclusions: During cancer-related hospitalizations, venous thromboembolism, particularly pulmonary embolism, functions as a major trigger for acute cardiac and hemodynamic decompensation rather than an isolated thrombotic event. These findings highlight VTE as a key driver of inpatient severity, critical care utilization, and mortality in oncology populations.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (6)

C

Christopher Aboujaoude

HCA Sunrise Health GME Consortium - MountainView Hospital, Las Vegas, NV

S

Sharnvir Chattha

HCA Sunrise Health GME Consortium - MountainView Hospital, Las Vegas, NV

B

Boone Singtong

HCA Sunrise Health GME Consortium - MountainView Hospital, Las Vegas, NV

D

Daniel Thomas Jones

HCA Sunrise Health GME Consortium - MountainView Hospital, Las Vegas, NV

P

Pinak Shah

From Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, NJ (P.G.); Columbia University Medical Center/New York Presbyterian Hospital (A.S., R.T.H., M.B.L.), the Cardiovascular Research Foundation (D.J.C., R.T.H., B.R., M.B.L.), and Weill Cornell Medicine (B.R.), New York, and St. Francis Hospital and Heart Center, Roslyn (D.J.C.) — all in New York; University of Colorado Health, Medical Center of the Rockies, Loveland (J.B.O.); Laval University, Quebec, QC (P.P.), St. Paul’s Hospital, University of British Columbia, Vancouver (P.B., J.L.), and McMaster University, Hamilton, ON (T.S.) — all in Canada; Vanderbilt University Medical Center, Nashville (B.R.L., K.G.); Emory University, Atlanta (V.B.); the Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, Stanford (W.F.F.), VA Palo Alto Health Care System, Palo Alto (W.F.F.), California Pacific Medical Center, San Francisco (D.V.D.), Cedars–Sinai Medical Center, Los Angeles (R.R.M.), and Edwards ...

K

Kyaw Zin Thein

3Comprehensive Cancer Centers of Nevada, Division of Hematology and Medical Oncology, Las Vegas, United States